

Nano-Suspension A Tool for Enhancing Bioavailability : A Systematic Review

Akshay R. Gadhari, Vaishali N. Tidke, Renuka G. Pawar

Lecturer, Dr. Y S Khedkar College of Pharmacy, Aurangabad

Abstract: *Nanosuspension technological know-how solved the drawback of medications which are inadequately watery dissolvable and less bioavailability. Steadiness and bioavailability of the medications can be expanded by means of the Nanosuspension technology. Coaching of Nanosuspension is simple and relevant to all medicinal drugs which are fluid insoluble. Nanosuspensions are readied through utilizing wet mill, high strain homogenizer, emulsion solvent evaporation, melt emulsification approach and super significant fluid systems. Nanosuspension can be prepared with the aid of using stabilizers, natural and organic solvents and different components such as buffers, salts, polyols, osmogent and cry protectant. Nanosuspensions can likewise be delivered with the aid of oral, parenteral, aspiratory and visual courses. Nanosuspensions can additionally be used for distinct drug supply when included in the ocular inserts and mucoadhesive hydrogels.*

Keywords: Nanosuspension, Lipid solubility, Particle size, Oral bioavailability

REFERENCES

- [1]. Patelm, Shah A, Dr.Patel NM, Dr.Patel MR, Dr.Patel KR. Nanosuspension: A novel approach for drug delivery system. Journal of Pharmaceutical Science & Bioscientific Research, 2011; 1(1): 1-10.
- [2]. Kocbek P, Baumgartner S, Krist J. Preparation and evaluation of nanosuspensions for enhancing the dissolution of poorly soluble drugs. International Journal of Pharmaceutics, 2006; 312: 179-86.
- [3]. Lenhardt T, Vergnault G, Grenier P, Scherer D, Langguth P. Evaluation of nanosuspension for absorption enhancement of poorly soluble drugs: invitro transport studies across intestinal epithelial monolayers. The aaps journal, 2008; 10(3): 435-438.
- [4]. Arunkumar N, Mand D, Rani C. Nano suspension technology and its application in drug delivery. Asian Journal of Pharmaceutics, 2009; 3: 168-173
- [5]. Xiaohui P, Sun J, Mol L, Zhonggui H. Formulation of nanosuspensions as a new approach for the delivery of poorly, current nanoscience. Bentham science publishers ltd, 2009, 5: 417-427.
- [6]. Liversidge GG, Cundy KC. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs: absolute oral bioavailability of nanocrystalline danazol. Int J Pharm, 2005; 125(1): 91-97.
- [7]. Shid RL, Dhole SN, Kulkarni N, Shid SL. Nanosuspension: A Review. Int J. Pharm. Sci. Rev. Res, 2013, 22(1): 98-106.
- [8]. Dhanapal R, Ratna JV. Nanosuspensions technology in drug delivery – a review. Int J Pharm Rev Res, 2012; 2(1): 46-52.
- [9]. Rathod P. Nano suspension Approach for Drug Delivery System: A Review. Journal of Emerging Technologies and Innovative Research, 2019; 9(5): 458-461.
- [10]. Patel HM, Patel BB, Dr. Shah CN. Nanosuspension: A novel approach to enhance solubility of poorly water soluble drugs - A review. International Journal of Advances in Pharmaceutics, 2016; 5(2): 21-29.
- [11]. Purkayastha HD, Hossain SK. Nanosuspension: A modern technology used in drug delivery system. International Journal of Current Pharmaceutical Research, 2019; 11(3): 1-3.
- [12]. Kavitha VB, Neethu CS, Dineshkumar B, Krishnakumar K, John A. Nanosuspension Formulation: An Improved Drug Delivery System. Nanoscience and Nanotechnology: An International Journal, 2014; 4(1): 1-5

- [13]. N.A.M.Deecaraman, C.Rani, Mohanraj KP, Kumar KV, preparation and solid state characterization of atorvastatin nanosuspensions for enhanced solubility and dissolution, *International Journal of PharmTech Research*, 1, 2009, 1725-1730.
- [14]. Patel DJ, Patelj K, Pandya VM, 3rishad R. Jivani RR, Patel RD, Optimization of Formulation Parameters On Famotidine Nanosuspension Using Factorial Design And The Desirability Function, *International Journal of PharmTech Research*, 2, 2010, 155-161.
- [15]. Patil MS, Preparation And Optimization of Simvastatin Nanoparticle For Solubility Enhancement And In-Vivo Study, *International Journal of Pharma Research and Development – Online*, 2, 2011, 219-226.
- [16]. Wei Li, Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension, *International Journal of Pharmaceutics*, 408, 2011, 157-162.
- [17]. Jorvekar.P, Pathak AA, Chaudhari PD, Formulation Development of Aceclofenac Loaded Nanosuspension by Three Square (3²) Factorial Design, *International Journal Of Pharmaceutical Sciences and Nanotechnology*, 4, 2012, 1575-1582.
- [18]. Banavath H. Sivarama RK, Tahir A, Sajid A, Pattnaik G, Nanosuspension: an attempt to enhance bioavailability of poorly soluble drugs, *International Journal of Pharmaceutical Science and Research*, 1(9), 2010, 1-11.
- [19]. Shegokar R, Müller RH, Nanocrystals: Industrially feasible multifunctional formulation technology for poorly soluble actives, *International Journal of Pharmaceutics*, 399, 2010, 129–139.
- [20]. Chingunpituk J, Nanosuspension Technology for Drug Delivery, *Walailak J Sci& Tech*, 4(2), 2007, 139-153.
- [21]. Patravale B, Abhijit AD, Kulkarni RM, Nanosuspensions: a promising drug delivery strategy, *Journal of Pharmacy and Pharmacology*, 56, 2004, 827–840.
- [22]. Prasanna L, Nanosuspension Technology: A Review, *International Journal of Pharmacy and Pharmaceutical Sciences*, 2(4), 2010, 35-40.
- [23]. Xiaohui P, Jin S, Mo L, Zhonggui H, Formulation of Nanosuspensions as a New Approach for the Delivery of Poorly Soluble Drugs, *Current Nanoscience*, 5, 2009, 417- 427.
- [24]. Mohanty S, Role of Nanoparticles in Drug Delivery System, *International Journal of Research in Pharmaceutical and Biomedical Sciences*, 1 (2), 2010, 41-66. Ch.P, A Review On Nanosuspensions In Drug Delivery, *International Journal Of Pharma and Bio Sciences*, 2, 2011, 549-558.
- [25]. Nagare SK, A review on Nanosuspension: An innovative acceptable approach in novel delivery system, *Universal Journal of Pharma and Bio Sciences*, 2, 2011, 549-558.
- [26]. Nagare SK, A review on Nanosuspension: An innovative acceptable approach in novel delivery system, *Universal Journal of Pharmacy*, 1(1), 2012, 19-31.
- [27]. Debjit B, Nanosuspension -A Novel Approaches In Drug Delivery System, *ThePharma Innovation – Journal*, 1(12), 2012, 50-63.
- [28]. Kamble VA, Nanosuspension A Novel Drug Delivery System, *International Journal of PharmaAnd Bio Sciences*, 1, 2010, 352-360.
- [29]. Soni S, Nanosuspension: An Approach to Enhance Solubility of Drugs, *IJPI's Journal of Pharmaceutics and Cosmetology*, 2(9), 2012, 50-63.
- [30]. Wagh KS, Patil SK, Akarte AK, Baviskar DT, Nanosuspension - A New Approach of Bioavailability Enhancement, *International Journal of Pharmaceutical Sciences Review And Research*, 8, 2011, 61-65.
- [31]. Patil SA, Rane BR, Bakliwal SR, Pawar SP, Nanosuspension: At A Glance, *International Journal Of Pharmaceutical Science*, 3(1), 2011, 947-960.
- [32]. Bansal.S, Bansal M, Kumria R, Nanocrystals: Current Strategies and Trends, *International Journal of Research in Pharmaceutical and Biomedical Sciences*, 3 (1), 2012, 406- 419.
- [33]. Cornelia MK, Muller RH, Drug nanocrystals of poorly soluble drugs produced by high pressure homogenization, *European Journal of Pharmaceutics and Biopharmaceutics*, 62, 2006, 3–16.
- [34]. Pintu KD, Nanosuspensions: Potent vehicles for drug delivery and bioavailability enhancement of lipophilic drugs, *Journal of Pharmacy Research*, 5(3), 2012, 1548- 1554.

- [35]. Prasanta D, Nanotechnology For The Delivery of Poorly Water Soluble Drugs, The Global Journal Of Pharmaceutical Research, 1(3), 2012, 225-250.
- [36]. Patel M, Nanosuspension: A Novel Approach For Drug Delivery System, JPSBR, 1, 2011, 1-10.
- [37]. Shelke PV, A Review On Formulation And Evaluation of Nanosuspension, International Journal of Universal Pharmacy And Life Sciences, 2(3), 2012, 516-524.
- [38]. Venkatesh T, Nanosuspensions: Ideal Approach for the Drug Delivery of Poorly Water Soluble Drugs, Der Pharmacia Lettre, 3(2), 2011, 203-213.
- [39]. Yadav GV, Nanosuspension: A Promising Drug Delivery System, Pharmacophore, 3(5), 2012, 217-243.
- [40]. Pandey S, Nanosuspension: Formulation, Characterization and Evaluation, International Journal of Pharma and Bio Sciences, 1(2), 2010, 1-10.
- [41]. Toshi C, A Review on Nanosuspensions promising Drug Delivery Strategy, Current Pharma Research, 3(1), 2012, 764-776.
- [42]. Ezeddin K, Nanodispersions Platform for Solubility Improvement, International Journal of Research in Pharmaceutical and Biomedical Sciences, 4 (2), 2013, 636- 643.
- [43]. Kumar GP, Nanosuspensions: The Solution to Deliver Hydrophobic Drugs, International Journal of Drug Delivery, 3, 2011, 546-557.
- [44]. Kumar BS, Review Article Increasing Possibilities of Nanosuspension, Journal of Nanotechnology, 2013, 1-12.
- [45]. Battula SR, Nano Fabricated Drug Delivery Devices, International Journal of Pharmacy & Technology, 4 (1), 2012, 1974-1986.
- [46]. Venkatesh T, Nanosuspensions: Ideal Approach for the Drug Delivery of Poorly Water Soluble Drugs, Der Pharmacia Lettre, 3(2), 2011, 203-213.
- [47]. Paun JS, Nanosuspension: An Emerging Trend for Bioavailability Enhancement of Poorly Soluble Drugs, Asian J. Pharm. Tech, 2(4), 2012, 157-168.
- [48]. Vaghela A, Nanosuspension Technology, International Journal of Universal Pharmacy and Life Sciences, 2(2), 2012, 306-317.
- [49]. Bhargavi A, Technical Review of Nanosuspensions, International Journal of Pharmacy & Technology, 3(3), 2011, 1503-1511.
- [50]. Verma KAK, Nanosuspensions: Advantages and Disadvantages, Indian Journal of Novel Drug Delivery, 4(3), 2012, 179-188.
- [51]. Srinivasa RK, an Overview of Statins as Hypolipidemic Drugs, International Journal of Pharmaceutical Sciences and Drug Research, 3(3), 2011, 178-183.
- [52]. Nagaraju P, Nanosuspension: A Promising Drug Delivery System, International Journal of Pharmaceutical Sciences and Nanotechnology, 2(4), 2010, 679-684.
- [53]. Koteswara KB, Nanosuspension: A Novel Drug Delivery Approach, IJRAP, 2(1), 2011, 162-165.
- [54]. Mudgil M, Gupta N, Nagpal M, Pawar P, Nanotechnology: A New Approach For Ocular Drug Delivery System, International Journal Of Pharmacy And Pharmaceutical Sciences, 4(2), 2012, 105-112.
- [55]. Sebestik J, et al. applications, Amino Acids.(2011);40:301-70.
- [56]. Adenovirus dodecahedron, a new vector for human gene transfer, van den Berg A and Dowdy SF. Protein transduction domain delivery of therapeutic macromolecules, Curr Opin Biotechnol.(2011);22:888-93.
- [57]. Sumida SM, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein, J Immunol.(2005);174:7179-85.
- [58]. Fuschiotti P, et al. Structure of the dodecahedral penton particle from human adenovirus type 3, J Mol Biol.(2006);356:510-20.
- [59]. Sonenberg N and Gingras AC. (1998) The mRNA 5' cap-binding protein eIF4E and control of cell growth, Curr Opin Cell Biol.(1998);10:268-75.
- [60]. Protein transduction into human cells by adenovirus dodecahedron using WW domains as universal adaptors,

- [61]. Lejbkowicz F, et al. A fraction of the mRNA 5' cap-binding protein, eukaryotic initiation factor 4E, localizes to the nucleus, *Proc Natl Acad Sci U S A.* (1992);89:9612-6.
- [62]. Adenovirus dodecahedron, as a drug delivery vector,
- [63]. Kowalska J, et al. Phosphorothioate analogs of m7GTP are enzymatically stable inhibitors of capdependent translation, *Bioorg Med Chem Lett.* (2009);19:1921-5.
- [64]. Zochowska M, et al. Virus-like particle-mediated intracellular delivery of mRNA cap analog with in vivo activity against hepatocellular carcinoma, *Nanomedicine.* (2015);11:67-76.
- [65]. Malika Vet al. Nano-Carrier for accentuated transdermal drug delivery. *J Develop Drugs.* 2014;3:121.
- [66]. Gestal MC and Escalante S. New initiative in Ecuador, the creation of a national reference laboratory for antibiotic resistance. *J Develop Drugs.* 2014;3:122.
- [67]. Sarkar Set al. Differential electrostatic interactions between granular species in a simple hopper chute geometry. *J Develop Drugs.* 2014;3:123.
- [68]. Joachim Müller et al. Escherichia coli are susceptible to thiazolidines if the tolC efflux system is inhibited. *J Develop Drugs.* 2014;3:124.
- [69]. Matsumoto Set al. In vitro synergistic effects of anthracycline antitumor agents and fluconazole against azole-resistant candida albicans clinical isolates. *J Develop Drugs.* 2014;3:125.
- [70]. Carvalho LP et al. Anti-Parasite effects of new thiosemicarbazones and their products thiazolidinone including cellular aspects of intracellular elimination of trypanosomacruzi in vitro. *J Develop Drugs.* 2014;3:126.
- [71]. Sebestik J, et al. applications, *Amino Acids.* (2011);40:301-70.
- [72]. Adenovirus dodecahedron, a new vector for human gene transfer, van den Berg A and Dowdy SF. Protein transduction domain delivery of therapeutic macromolecules, *Curr Opin Biotechnol.* (2011);22:888-93.
- [73]. Sumida SM, et al. Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein, *J Immunol.* (2005);174:7179-85.
- [74]. Fuschioti P, et al. Structure of the dodecahedral penton particle from human adenovirus type 3, *J Mol Biol.* (2006);356:510-20.
- [75]. Sonenberg N and Gingras AC. (1998) The mRNA 5' cap-binding protein eIF4E and control of cell growth, *Curr Opin Cell Biol.* (1998);10:268-75.
- [76]. Protein transduction into human cells by adenovirus dodecahedron using WW domains as universal adaptors,
- [77]. Lejbkowicz F, et al. A fraction of the mRNA 5' cap-binding protein, eukaryotic initiation factor 4E, localizes to the nucleus, *Proc Natl Acad Sci U S A.* (1992);89:9612-6.
- [78]. Adenovirus dodecahedron, as a drug delivery vector,
- [79]. Kowalska J, et al. Phosphorothioate analogs of m7GTP are enzymatically stable inhibitors of capdependent translation, *Bioorg Med Chem Lett.* (2009);19:1921-5.
- [80]. Zochowska M, et al. Virus-like particle-mediated intracellular delivery of mRNA cap analog with in vivo activity against hepatocellular carcinoma, *Nanomedicine.* (2015);11:67-76.
- [81]. Malika Vet al. Nano-Carrier for accentuated transdermal drug delivery. *J Develop Drugs.* 2014;3:121.
- [82]. Gestal MC and Escalante S. New initiative in Ecuador, the creation of a national reference laboratory for antibiotic resistance. *J Develop Drugs.* 2014;3:122.
- [83]. Sarkar Set al. Differential electrostatic interactions between granular species in a simple hopper chute geometry. *J Develop Drugs.* 2014;3:123.
- [84]. Joachim Müller et al. Escherichia coli are susceptible to thiazolidines if the tolC efflux system is inhibited. *J Develop Drugs.* 2014;3:124.
- [85]. Matsumoto Set al. In vitro synergistic effects of anthracycline antitumor agents and fluconazole against azole-resistant candida albicans clinical isolates. *J Develop Drugs.* 2014;3:125.
- [86]. Carvalho LP et al. Anti-Parasite effects of new thiosemicarbazones and their products thiazolidinone including cellular aspects of intracellular elimination of trypanosomacruzi in vitro. *J Develop Drugs.* 2014;3:126.



- [87]. KanwarSSet al. Personalized medicine through circulating tumor cells: the new dimension in cancer research. *J Develop Drugs*. 2013;2:e128
- [88]. Vaidya A. Drug designing and development: emerging role of health technology assessment. *Drug Des*. 2014;3:111.
- [89]. Chow SC and Pong A. Statistical designs for pharmaceutical/clinical development. *Drug Des*. 2014;3:112.
- [90]. JokanovicV. The deep scientific and philosophic approach to the future nanomedicine, given on the base of author 47. introduction in the monograph “nanomedicine, the greatest challenge of the 21st century”. *Drug Des*.2014;3:113.
- [91]. Gomase VS and Chitlange NR. Sensitive quantitative predictions of mhc binding peptides and fragment based peptide vaccines from trichinellasprialis. *Drug Des*. 2014;1:101.
- [92]. Den Haan Het al. Application of modern drug discovery techniques in the context of diabetes mellitus and atherosclerosis. *Drug Des*. 2015;4:e125.
- [93]. Gomase VS and Kale KV. Information of surface accessibility of the peptide fragments of coat protein from alfalfamosaic virus (amv) at the physicochemical and immunochemical levels. *Drug Des*. 2015;4:119. 51. Yuh-JennWuet al. Evaluating the relative cost of a targeted design versus an untargeted design for randomized clinical trials. *Drug Des*. 2015;4:120.
- [94]. BuleMHet al. Synthesis and in-vivo pharmacological evaluation of some novel 4(3h)- 53. quinazolinone derivatives as potential anti-malarial agents. *Drug Des*. 2015;4:121.
- [95]. Soave Cet al. Repositioning an old antialcoholism drug: disulfiram as a selective, effective and economical anticancer agent. *J Develop Drugs*. 2016;5:e147.
- [96]. Sreelakshmy Vet al. Green synthesis of silver nanoparticles from glycyrrhizaglabra root extract for the treatment of gastric ulcer. *J Develop Drugs*. 2016;5:152
- [97]. Reure J, et al. Her2 Positive Metastatic Breast Cancer Patient without Any Sign of Recurrence 5 years after Cessation of Trastuzumab: A Case Report *ClinPharmacolBiopharm*. 2015;4:136.
- [98]. Morin C, et al. Late Onset Infections after Surgical Treatment of Spinal Deformities in Children. *J Spine*. 2015;4:262.
- [99]. Bhat IH, et al. Clinical Profile and Outcome in Distal Gastrointestinal Tract Obstruction in Neonates with Special Emphasis on Role of Colostomy and its Complications. *Anat Physiol*. 2016;6:222.
- [100]. Abbas A. Screening and Prevention of Transmission of HIV-1 in Neonates Born to Mothers with HIV. *Int J Pub Health Safe*. 2016; 1:103.
- [101]. Saito M, et al. High Dose Octreotide for the Treatment of Chylothorax in Three Neonates. *J Neonatal Biol*. 2016;5:218.
- [102]. Ogbalu OK, et al. A New Trend of Omphalitis Complicated with Myiasis in Neonates of the Niger Delta, Nigeria. *Epidemiology Sunnyvale*. 2016;6:231. 62. Kurt A, et al. Exposure to Environmental Tobacco Smoke during Pregnancy Restrain the Antioxidant Response of their Neonates. *J Neonatal Biol*. 2016;5:210.
- [103]. Kondo M.NPC-11 Phase III Trial Concerning Apnea of Prematurity in Japanese Neonates: A Study of Safety, Efficacy and Pharmacokinetics. *Pharm Anal Acta*. 2016;7:458.
- [104]. Garcia AJ and Smith JM Bile Duct Brushings in a Jaundiced Woman. 2015.
- [105]. Alvarez AM, et al. Non-communicating Mucinous Biliary Cystadenoma as a Rare Cause of Jaundice. *J CytolHistol*. 2015; 6:369. 66. Morin C, et al. Late Onset Infections after Surgical Treatment of Spinal Deformities in Children. *J Spine*. 2015; 4:262.
- [106]. Lopes CM. Therapeutics delivery: innovations technology approaches. *Lopes, Drug Des*. 2014;3:e123.
- [107]. Chow SC. On assessment of analytical similarity in biosimilar studies. *Drug Des*. 2014;3:e124.
- [108]. Lu Qet al. On two-stage adaptive seamless design with count data from different study durations under weibull distribution. *Drug Des*. 2014;3:114.
- [109]. Sherkhane AS and Gomase VS. Identification of binding affinity of tap peptides for development of fragment based vaccine from long neurotoxin 2 [N. naja]. *Drug Des*. 2014;3:115.
- [110]. Toshihiko T. Multifunctionality of drug’s pharmacophores within an organism. *Drug Des*. 2014;3:116.



- [111]. Bielecka AM and Obuchowicz E. Chronic physiological hypoxia and high glucose concentration promote resistance of t98g glioblastoma cell line to temozolomide. *Drug Des.* 2014;3:117.
- [112]. Stoicescu M and Bungau S. Contraceptive pills consumption risk factor of the breast cancer original case report. *Drug Des.* 2014;3:118.
- [113]. Lopes CM and Soares C. Transdermal drug delivery systems activated by physical stimuli: techniques and applications. *Drug Des.* 2015;4:e129.
- [114]. El-Bastawissy EA and Elhasab MA. Molecular docking and molecular dynamic simulation: insight into the difference in binding of hcv ns3/4a macrocyclic inhibitors to genotypes 1b and 4a. *Drug Des.* 2015;4:124.
- [115]. Fang J. Reliability of machine learning based algorithms for designing protein drugs with enhanced stability. *Drug Des.* 2015;4:e130
- [116]. Tutar L et al. Structure Based Drug Design for Heat Shock Proteins. *Drug Des* 2016;5:e130.
- [117]. Ceron-Carrasco JP et al. Application of computational drug discovery techniques for designing new drugs against zika virus. *Drug Des.* 2016;5:e131.
- [118]. Gopi S et al. Effective drug delivery system of biopolymers based on nanomaterials and hydrogels -a review. *Drug Des.* 2016;5:129.
- [119]. Ogikubo Y and Akitsu T. Enhancing medical or biological functions of laccase by cyanide-bridged Cu(II)-Fe(III) bimetallic complexes mediators. *Drug Des.* 2016;5:130.
- [120]. Kahouli et al. Characterization of *L. reuteri* NCIMB 701359 probiotic features for potential use as a colorectal
- [121]. cancer biotherapeutic by identifying fatty acid profile and anti-proliferative action against colorectal cancer cells. *Drug Des.* 2016;5:131.
- [122]. Chow SC and Song F. Reproducible clinical research. *Drug Des.* 2016;5:132.
- [123]. Damodar R et al. Formulation and evaluation of fast dissolving tablets of diclofenac sodium by novel hole technology. *J Mol Pharm Org Process Res.* 2014;2:116.
- [124]. Yuh-Jenn W et al. Evaluating the relative cost of a targeted design versus an untargeted design for randomized clinical trials. *Drug Des.* 2015;4:12
- [125]. Bule MH et al. Synthesis and in-vivo pharmacological evaluation of some novel 4(3h)-quinazolinone derivatives as potential anti-malarial agents. *Drug Des.* 2015;4:121
- [126]. Soave C et al. Repositioning an old anti-alcoholism drug: disulfiram as a selective, effective and economical anticancer agent. *J Develop Drugs.* 2016;5:e147.
- [127]. Sreelakshmy V et al. Green synthesis of silver nanoparticles from glycyrrhizalabra root extract for the treatment of gastric ulcer. *J Develop Drugs.* 2016;5:152
- [128]. Reure J, et al. Her2 Positive Metastatic Breast Cancer Patient without Any Sign of Recurrence 5 years after Cessation of Trastuzumab: A Case Report *Clin Pharmacol Biopharm.* 2015;4:136.
- [129]. Morin C, et al. Late Onset Infections after Surgical Treatment of Spinal Deformities in Children. *J Spine.* 2015;4:262.
- [130]. Bhat IH, et al. Clinical Profile and Outcome in Distal Gastrointestinal Tract Obstruction in Neonates with Special Emphasis on Role of Colostomy and its Complications. *Anat Physiol.* 2016;6:222.